Can anything shut down the Gold rally?
Director Sanders Corazon (Corsee) D. of BeOne Medicines Ltd (NASDAQ:ONC) sold 2,665 American Depositary Shares of the company on September 5, 2025. The shares were sold at a price of $337, totaling $898,105. The transaction comes as ONC trades near its 52-week high of $351.27, having delivered an impressive 90.1% return year-to-date.
On the same day, Sanders also acquired 2,665 American Depositary Shares at a price of $155.68, for a total value of $414,887. Additionally, Sanders exercised options to purchase 34,645 ordinary shares at an exercise price of $11.98.
Following these transactions, Sanders directly holds 57,226 ordinary shares.
In other recent news, BeOne Medicines has announced several key developments. The company reported positive topline results from a Phase 1/2 study of sonrotoclax in patients with relapsed/refractory mantle cell lymphoma, meeting its primary endpoint of overall response rate. Additionally, BeOne Medicines secured a $950 million royalty deal with Royalty Pharma, involving the sale of its royalty rights on worldwide sales of Amgen’s IMDELLTRA®, with an upfront payment of $885 million. The European Commission has also approved TEVIMBRA for the treatment of resectable non-small cell lung cancer, showing significant survival benefits in a Phase 3 trial.
In analyst updates, Citizens JMP has reiterated its Market Outperform rating on BeOne Medicines with a price target of $348.00, highlighting two key value drivers for the company. These recent developments reflect significant progress in BeOne Medicines’ research and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.